Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172871 | 0.88 | HSD11B1 (0.50) | HSD11B1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4172300 | 0.83 | HSD11B1 (0.43) | HSD11B1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4172728 | 0.82 | HSD11B1 (0.49) | HSD11B1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4604575 | 0.82 | HSD11B1 (0.46) | HSD11B1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4185341 | 0.81 | HSD11B1 (0.47) | HSD11B1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4177574 | 0.78 | HSD11B1 (0.45) | HSD11B1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4175343 | 0.71 | SOAT1 (0.46) | HSD11B1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL13778892 | 0.68 | SOAT1 (0.46) | HSD11B1MEN1KMT2AMAPTSOAT1 | |
| SCHEMBL13302731 | 0.67 | SOAT1 (0.48) | HSD11B1MEN1KMT2AMAPTSOAT1 | |
| SCHEMBL4172855 | 0.66 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | HSD11B1 1690/4885MEN1 1676/4885KMT2A 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.